Mehta R R, Graves J M, Warso M A, Das Gupta T K
Department of Surgical Oncology, University of Illinois at Chicago 60612, USA.
Br J Cancer. 1995 Nov;72(5):1160-4. doi: 10.1038/bjc.1995.480.
We established a panel of 17 xenografts from primary human breast carcinomas. We examined which characteristics of the original tumours and the xenografts facilitate growth in animals. Tumours expressing medium or strong immunoreactivity for p53 protein had significantly (P < 0.05) higher incidence (92%) of in vivo tumour take than those showing weak or negative immunoreactivity (9.1%). No such association was observed between either c-erbB-2 or epidermal growth factor receptor (EGFR) expression in the original tumours and their in vivo tumour take. Following subcutaneous (s.c.) transplantation of original breast tumours or established xenografts, 7/17 tumours showed metastatic disease spread to distant sites (mainly lungs). This study suggests that selective growth of highly aggressive tumours occurs during in vivo propagation of malignant tumours, and these tumours will be of particular interest in evaluating various chemotherapeutic agents for breast cancer management.
我们建立了一个由17种原发性人类乳腺癌异种移植组成的小组。我们研究了原发肿瘤和异种移植的哪些特征有助于在动物体内生长。对p53蛋白表达中度或强免疫反应性的肿瘤在体内肿瘤形成的发生率（92%）显著高于（P < 0.05）显示弱免疫反应性或阴性免疫反应性的肿瘤（9.1%）。在原发肿瘤中的c-erbB-2或表皮生长因子受体（EGFR）表达与其体内肿瘤形成之间未观察到此类关联。在对原发乳腺肿瘤或已建立的异种移植进行皮下（s.c.）移植后，17个肿瘤中有7个显示转移性疾病扩散至远处部位（主要是肺部）。这项研究表明，在恶性肿瘤的体内增殖过程中会发生高侵袭性肿瘤的选择性生长，并且这些肿瘤在评估用于乳腺癌治疗的各种化疗药物时将具有特别的意义。
